KEY FINDINGS
The Europe DNA sequencing market is set to record a CAGR of 17.23% during the forecast period, 2021-2028. The increasing prioritization of DNA sequencing and the biotechnology industry due to technological innovations in the DNA sequencing platforms, cloud computing applications to store DNA sequencing data, data storage & management, etc., drives the market growth.
MARKET INSIGHTS
The United Kingdom, Italy, Russia, Poland, Belgium, France, Germany, and Rest of Europe are assessed for the Europe DNA sequencing market growth evaluation. In Germany, the growing prevalence of diseases has resulted in increased investments in the medical research and healthcare sectors. Biotechnology companies and pharmaceuticals are investing considerably in personalized medicine, which is majorly dependent on next-generation sequencing. Most academic institutions accommodate such facilities. Moreover, hospitals and healthcare facilities are projected to get more advanced technologies in the next few years.
In France, the rising healthcare expenditure and growing incidence of diseases propel market growth. Also, the R&D expenditure is expected to increase during the forecast period. The government initiatives further drive market growth. For instance, the French Plan for Genomic Medicine 2025, commissioned in 2015. In Russia, research centers like the Research Centre for Medical Genetics promote market growth. It is a federal non-profit academic research institution that leads in the medical genetics field. Whereas, in countries like Belgium, the increasing implementation of genomic research fuels market growth.
COMPETITIVE INSIGHTS
Some of the market’s prominent players include F. Hoffmann-La Roche, Bio-Rad Laboratories Inc, Danaher Corporation (Integrated DNA Technologies Inc), Asuragen Inc, Merck KGaA, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING NEED FOR DNA SEQUENCING IN ANIMALS & PLANT REPRODUCTION
3.1.2. TECHNOLOGICAL DEVELOPMENTS
3.1.3. GROWING RESEARCH AND DEVELOPMENT IN DNA SEQUENCING
3.1.4. PREVALENCE OF CANCER CASES
3.1.5. USAGE OF LIQUID BIOPSY APPLICATIONS
3.1.6. IMPLEMENTATION OF GENOME MAPPING PROGRAMS
3.2. KEY RESTRAINTS
3.2.1. ACCURACY AND STANDARDIZATION CONCERNS IN DIAGNOSTIC TESTING
3.2.2. LIMITATIONS IN BIOINFORMATICS
3.2.3. SOCIAL AND ETHICAL ISSUES
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON DNA SEQUENCING MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRY
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. VALUE CHAIN ANALYSIS
4.7. KEY BUYING CRITERIA
5. MARKET BY TECHNOLOGY
5.1. SEQUENCING BY SYNTHESIS
5.2. ION SEMICONDUCTOR SEQUENCING
5.3. CHAIN TERMINATION SEQUENCING
5.4. PYROSEQUENCING
5.5. SEQUENCING BY LIGATION (SBL)
5.6. SINGLE-MOLECULE REAL-TIME SEQUENCING (SMRT)
5.7. NANOPORE SEQUENCING
5.8. OTHER TECHNOLOGIES
6. MARKET BY APPLICATION
6.1. BIOMARKER DISCOVERY
6.2. DIAGNOSTICS
6.3. REPRODUCTIVE HEALTH
6.4. PERSONALIZED MEDICINE
6.5. DRUG DISCOVERY
6.6. AGRICULTURE & ANIMAL RESEARCH
6.7. FORENSICS
6.8. OTHER APPLICATIONS
7. MARKET BY PRODUCT
7.1. INSTRUMENTS & CONSUMABLES
7.1.1. INSTRUMENTS & CONSUMABLES TYPE
7.1.1.1. CONSUMABLES
7.1.1.2. INSTRUMENTS
7.1.2. INSTRUMENTS & CONSUMABLES PLATFORM
7.1.2.1. NGS (NEXT GENERATION SEQUENCING)
7.1.2.1.1. RNA SEQUENCING
7.1.2.1.2. TARGETED RESEQUENCING
7.1.2.1.3. WHOLE-EXOME SEQUENCING
7.1.2.1.4. WHOLE-GENOME SEQUENCING
7.1.2.1.5. CHIP SEQUENCING
7.1.2.1.6. DE NOVO SEQUENCING
7.1.2.1.7. METHYL SEQUENCING
7.1.2.2. SANGER
7.2. SEQUENCING SERVICES
7.3. BIOINFORMATICS
8. MARKET BY END-USER
8.1. RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
8.2. PHARMACEUTICAL
8.3. BIOTECHNOLOGY COMPANIES
8.4. HOSPITALS & CLINICS
8.5. OTHER END-USERS
9. GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. GERMANY
9.1.5.2. FRANCE
9.1.5.3. UNITED KINGDOM
9.1.5.4. ITALY
9.1.5.5. RUSSIA
9.1.5.6. BELGIUM
9.1.5.7. POLAND
9.1.5.8. REST OF EUROPE
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS & AGREEMENTS
10.1.4. BUSINESS EXPANSIONS, ANNOUNCEMENTS, AND DIVESTITURES
10.2. COMPANY PROFILES
10.2.1. ADAPTIVE BIOTECHNOLOGIES INC
10.2.2. AGILENT TECHNOLOGIES INC
10.2.3. ASURAGEN INC
10.2.4. BGI GENOMICS
10.2.5. BIO-RAD LABORATORIES INC
10.2.6. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
10.2.7. EUROFINS SCIENTIFIC
10.2.8. F. HOFFMANN-LA ROCHE
10.2.9. ILLUMINA INC
10.2.10. MERCK KGAA
10.2.11. PACIFIC BIOSCIENCES OF CALIFORNIA INC
10.2.12. PERKINELMER INC
10.2.13. SIEMENS HEALTHINEERS AG
10.2.14. SPIRAL GENETICS INC
10.2.15. THERMO FISHER SCIENTIFIC INC
10.2.16. UBIQUITY GENOMICS INC
1. ADAPTIVE BIOTECHNOLOGIES INC
2. AGILENT TECHNOLOGIES INC
3. ASURAGEN INC
4. BGI GENOMICS
5. BIO-RAD LABORATORIES INC
6. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
7. EUROFINS SCIENTIFIC
8. F. HOFFMANN-LA ROCHE
9. ILLUMINA INC
10. MERCK KGAA
11. PACIFIC BIOSCIENCES OF CALIFORNIA INC
12. PERKINELMER INC
13. SIEMENS HEALTHINEERS AG
14. SPIRAL GENETICS INC
15. THERMO FISHER SCIENTIFIC INC
16. UBIQUITY GENOMICS INC
